| Autor: |
Zhang F; School of Biological Sciences, University of Hong Kong, Pokfulam, Hong Kong 000, S.A.R., China., Lo EKK; School of Biological Sciences, University of Hong Kong, Pokfulam, Hong Kong 000, S.A.R., China., Chen J; State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong 000, S.A.R., China.; Department of Medicine, The University of Hong Kong, Hong Kong 000, S.A.R., China.; Leibniz Institute for Natural Product Research and Infection Biology, Hans Knöll Institute-Microbiome Dynamics, Jena D-07745, Germany., Wang K; Department of Food Science and Nutrition, The Hong Kong Polytechnic University, Hong Kong 000, S.A.R., China.; Research Institute for Future Food, The Hong Kong Polytechnic University, Hong Kong 000, S.A.R., China., Felicianna; School of Biological Sciences, University of Hong Kong, Pokfulam, Hong Kong 000, S.A.R., China., Ismaiah MJ; School of Biological Sciences, University of Hong Kong, Pokfulam, Hong Kong 000, S.A.R., China., Leung HKM; School of Biological Sciences, University of Hong Kong, Pokfulam, Hong Kong 000, S.A.R., China., Zhao D; Department of Food Science and Nutrition, The Hong Kong Polytechnic University, Hong Kong 000, S.A.R., China.; Research Institute for Future Food, The Hong Kong Polytechnic University, Hong Kong 000, S.A.R., China., Lee JC; School of Biological Sciences, University of Hong Kong, Pokfulam, Hong Kong 000, S.A.R., China., El-Nezami H; School of Biological Sciences, University of Hong Kong, Pokfulam, Hong Kong 000, S.A.R., China.; Institute of Public Health and Clinical Nutrition, School of Medicine, University of Eastern Finland, Kuopio FI-70211, Finland. |
| Abstrakt: |
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent metabolic disease that has no effective treatment. Our proprietary probiotic mixture, Prohep, has been proven in a previous study to be helpful in reducing hepatocellular carcinoma (HCC) in vivo. However, its prospective benefits on the treatment of other liver diseases such as MASLD, which is one of the major risk factors in the development of HCC, are unclear. To investigate the potential of Prohep in modulating the development and progression of MASLD, we first explored the effect of Prohep supplementation via voluntary intake in a high-fat diet (HFD)-induced MASLD/metabolic dysfunction-associated steatohepatitis (MASH) murine model. Our results indicated that Prohep alleviated HFD-induced liver steatosis and reduced excessive hepatic lipid accumulation and improved the plasma lipid profile when compared with HFD-fed control mice through suppressing hepatic de novo lipogenesis and cholesterol biosynthesis gene expressions. In addition, Prohep was able to modulate the gut microbiome, modify the bile acid (BA) profile, and elevate fecal short-chain fatty acid (SCFA) levels. Next, in a prolonged HFD-feeding MASLD/MASH model, we observed the effectiveness of Prohep in preventing the transition from MASLD to MASH via amelioration in hepatic steatosis, inflammation, and fibrosis. Taken together, Prohep could ameliorate HFD-induced MASLD and control the MASLD-to-MASH progression in mice. Our findings provide distinctive insights into the development of novel microbial therapy for the management of MASLD and MASH. |
